Contribute Try STAT+ Today

Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren’t there better treatments for brain cancer?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation about how a recent FDA rejection flies in the face of what had become conventional wisdom in the drug industry. Then we’ll talk about how the immunotherapy revolution in oncology has done little for glioblastoma, the cancer that killed Sen. John McCain. We’ll also dig into how a major trial on the cardiovascular benefits of fish oil could be a bad omen for Amarin and its efforts to turn a marginal product into a blockbuster. Finally, we’ll embark on a lightning round, covering the slow process of socialized medicine, the summer homes of sell-side analysts, and the future of digital medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.